Eli Lilly finalizes purchase of AtaiBeckley, expanding its pipeline for treatment-resistant depression and other mental health conditions

Eli Lilly has recently announced it has successfully closed its acquisition of AtaiBeckley Inc., a clinical-stage biopharmaceutical company developing fast-acting neuroplastogens for mental health conditions, including BPL-003, its lead investigational program targeting treatment-resistant depression.

Carole Ho, Lilly’s executive vice president and president of Lilly Neuroscience, said treatment-resistant depression continues to affect patients even after they’ve tried multiple treatments, leaving millions still searching for relief. She said AtaiBeckley’s neuroplastogens have the potential to introduce a new treatment paradigm, offering fast-acting therapeutics designed to move away from the need for chronic dosing. She described the approach as exactly the kind of innovation the field needs, and said Lilly is committed to advancing these therapies for patients who need more options.

The deal was approved by AtaiBeckley shareholders during a special meeting held ahead of closing.

---

---

Related Topics and Keywords

AtaiBeckley, Eli Lilly, treatment-resistant depression